Genetics and pharmacogenomics of diffuse gliomas

Hinke Foka van Thuijl; B. Ylstra; T. Würdinger; D. Van Nieuwenhuizen; Jan J. Heimans; P. Wesseling; Jaap C. Reijneveld

doi:10.1016/j.pharmthera.2012.09.002

Genetics and pharmacogenomics of diffuse gliomas

Hinke Foka van Thuijl, B. Ylstra, T. Würdinger, D. Van Nieuwenhuizen, Jan J. Heimans, P. Wesseling, Jaap C. Reijneveld

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Rapidly evolving techniques for analysis of the genome provide new opportunities for cancer therapy. For diffuse gliomas this has resulted in molecular markers with potential for personalized therapy. Some drugs that utilize pharmacogenomics are currently being tested in clinical trials. In melanoma, lung-, breast-, gastric- and colorectal carcinoma several molecular markers are already being clinically implemented for diagnosis and treatment. These insights can serve as a background for the promise and limitations that pharmacogenomics has for diffuse gliomas. Better molecular characterization of diffuse gliomas, including analysis of the molecular underpinnings of drug efficacy in clinical trials, is urgently needed. We foresee exciting developments in the upcoming years with clinical benefit for the patients.

Original language	English
Pages (from-to)	78-88
Number of pages	11
Journal	Pharmacology & Therapeutics
Volume	137
Issue number	1
DOIs	https://doi.org/10.1016/j.pharmthera.2012.09.002
Publication status	Published - Jan 2013

Keywords

1p/19q co-deletion
Companion diagnostics
EGFRvIII
Glioma
IDH1
Pharmacogenomics

Access to Document

10.1016/j.pharmthera.2012.09.002

Cite this

@article{8ecf7e8ccc91465b90f8ab224597ac6d,

title = "Genetics and pharmacogenomics of diffuse gliomas",

abstract = "Rapidly evolving techniques for analysis of the genome provide new opportunities for cancer therapy. For diffuse gliomas this has resulted in molecular markers with potential for personalized therapy. Some drugs that utilize pharmacogenomics are currently being tested in clinical trials. In melanoma, lung-, breast-, gastric- and colorectal carcinoma several molecular markers are already being clinically implemented for diagnosis and treatment. These insights can serve as a background for the promise and limitations that pharmacogenomics has for diffuse gliomas. Better molecular characterization of diffuse gliomas, including analysis of the molecular underpinnings of drug efficacy in clinical trials, is urgently needed. We foresee exciting developments in the upcoming years with clinical benefit for the patients.",

keywords = "1p/19q co-deletion, Companion diagnostics, EGFRvIII, Glioma, IDH1, Pharmacogenomics",

author = "{van Thuijl}, {Hinke Foka} and B. Ylstra and T. W{\"u}rdinger and {Van Nieuwenhuizen}, D. and Heimans, {Jan J.} and P. Wesseling and Reijneveld, {Jaap C.}",

year = "2013",

month = jan,

doi = "10.1016/j.pharmthera.2012.09.002",

language = "English",

volume = "137",

pages = "78--88",

journal = "Pharmacology & Therapeutics",

issn = "0163-7258",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Genetics and pharmacogenomics of diffuse gliomas

AU - van Thuijl, Hinke Foka

AU - Ylstra, B.

AU - Würdinger, T.

AU - Van Nieuwenhuizen, D.

AU - Heimans, Jan J.

AU - Wesseling, P.

AU - Reijneveld, Jaap C.

PY - 2013/1

Y1 - 2013/1

N2 - Rapidly evolving techniques for analysis of the genome provide new opportunities for cancer therapy. For diffuse gliomas this has resulted in molecular markers with potential for personalized therapy. Some drugs that utilize pharmacogenomics are currently being tested in clinical trials. In melanoma, lung-, breast-, gastric- and colorectal carcinoma several molecular markers are already being clinically implemented for diagnosis and treatment. These insights can serve as a background for the promise and limitations that pharmacogenomics has for diffuse gliomas. Better molecular characterization of diffuse gliomas, including analysis of the molecular underpinnings of drug efficacy in clinical trials, is urgently needed. We foresee exciting developments in the upcoming years with clinical benefit for the patients.

AB - Rapidly evolving techniques for analysis of the genome provide new opportunities for cancer therapy. For diffuse gliomas this has resulted in molecular markers with potential for personalized therapy. Some drugs that utilize pharmacogenomics are currently being tested in clinical trials. In melanoma, lung-, breast-, gastric- and colorectal carcinoma several molecular markers are already being clinically implemented for diagnosis and treatment. These insights can serve as a background for the promise and limitations that pharmacogenomics has for diffuse gliomas. Better molecular characterization of diffuse gliomas, including analysis of the molecular underpinnings of drug efficacy in clinical trials, is urgently needed. We foresee exciting developments in the upcoming years with clinical benefit for the patients.

KW - 1p/19q co-deletion

KW - Companion diagnostics

KW - EGFRvIII

KW - Glioma

KW - IDH1

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=84872300925&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2012.09.002

DO - 10.1016/j.pharmthera.2012.09.002

M3 - Article

AN - SCOPUS:84872300925

SN - 0163-7258

VL - 137

SP - 78

EP - 88

JO - Pharmacology & Therapeutics

JF - Pharmacology & Therapeutics

IS - 1

ER -

Genetics and pharmacogenomics of diffuse gliomas

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this